Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 205,566,896
  • Shares Outstanding, K 2,310,000
  • Annual Sales, $ 50,135 M
  • Annual Income, $ 7,703 M
  • 36-Month Beta 0.73
  • Price/Sales 3.90
  • Price/Cash Flow 11.76
  • Price/Book 2.62
  • Price/Earnings ttm 17.55
  • Earnings Per Share ttm 5.05
  • Most Recent Earnings 1.32 on 10/18/18
  • Next Earnings Date 01/23/19
  • Annual Dividend & Yield 1.91 (2.14%)
  • Most Recent Dividend 2.977 on 03/06/18
  • Sectors:

    Large Cap Pharma

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 1.34
  • Number of Estimates 3
  • High Estimate 1.41
  • Low Estimate 1.31
  • Prior Year 1.20
  • Growth Rate Est. (year over year) +11.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
82.07 +8.43%
on 12/27/18
89.21 -0.25%
on 01/18/19
+3.60 (+4.22%)
since 12/18/18
3-Month
82.07 +8.43%
on 12/27/18
92.39 -3.68%
on 12/04/18
+2.75 (+3.19%)
since 10/18/18
52-Week
72.30 +23.08%
on 06/28/18
94.19 -5.52%
on 01/26/18
+2.58 (+2.99%)
since 01/18/18

Most Recent Stories

More News
Lilly Stops Lartruvo Promotion as Confirmatory Study Fails

Eli Lilly's (LLY) Lartruvo combo is unable to demonstrate the clinical benefit for the primary endpoint of OS rate in a phase III study related to treating patients with metastatic soft tissue sarcoma....

NVO : 48.05 (+0.84%)
LLY : 116.59 (-2.16%)
NVS : 88.99 (+0.41%)
HLUYY : 43.8250 (-0.28%)
Kinaxis Selected to Accelerate Technical Operation Transformation of Major Pharmaceutical Company

Leading global medicines company to realize greater end-to-end visibility, better responsiveness, and improved decision making

NVS : 88.99 (+0.41%)
KXS.TO : 73.21 (+2.03%)
NVS or AZN: Which Is the Better Value Stock Right Now?

NVS vs. AZN: Which Stock Is the Better Value Option?

AZN : 36.55 (+0.72%)
NVS : 88.99 (+0.41%)
Intrexon Signs Licensing Agreement with Next Green Wave

Intrexon (XON) partners with Next Green Wave Holdings to utilize Intrexon's Botticelli next-generation plant propagation platform.

XON : 8.83 (+4.99%)
LLY : 116.59 (-2.16%)
TLRY : 77.20 (-7.49%)
NVS : 88.99 (+0.41%)
Ocular Inflammation Treatment Market is set to Grow US$ 500 Billion by 2024

New York, January 16, 2019: The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.

VRX.TO : 30.80 (-3.33%)
ALIM : 0.85 (+3.66%)
AGN : 160.22 (+2.34%)
NVS : 88.99 (+0.41%)
AKRX : 3.59 (unch)
PFE : 42.53 (+0.14%)
Keloid Treatment Market Key Manufactures and Opportunity Analysis By 2024

New York, January 16, 2019: Global is segmented based on the treatments type as, Occlusive Dressing, Compression Therapy, Cryosurgery, Excision, Radiation Therapy, Laser Therapy, Interferon Therapy, Intralesional...

VRX.TO : 30.80 (-3.33%)
GALE : 0.26 (-7.14%)
AVMXY : 1.8800 (+8.67%)
NVS : 88.99 (+0.41%)
SNOA : 0.82 (+2.50%)
GSK : 39.06 (+0.21%)
BMY : 50.12 (+1.05%)
PRGO : 45.97 (+2.45%)
Tilray Teams Up With Authentic Brands, Stock Down on Sell-Off

Tilray (TLRY) signs a marketing agreement with Authentic Brands Group to sell consumer cannabis products.

BUD : 73.65 (+2.32%)
TLRY : 77.20 (-7.49%)
NVS : 88.99 (+0.41%)
CGC : 43.52 (+1.75%)
6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019

Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.

LLY : 116.59 (-2.16%)
NVS : 88.99 (+0.41%)
TEVA : 18.82 (+0.32%)
AMGN : 203.88 (+0.97%)
Douglas G. Watson, Former CEO of Novartis Corporation, Joins Immunsys Board of Directors as Lead Independent Director

ImmunSYS, Inc., a clinical stage biotechnology company focused on the development of innovative cancer immunotherapy products, announced today that Douglas G. Watson joined its Board of Directors...

NVS : 88.99 (+0.41%)
Nick Haggar Appointed CEO of Zentiva

PRAGUE, January 15, 2019 /PRNewswire/ --

NVS : 88.99 (+0.41%)
GSK : 39.06 (+0.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade NVS with:

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

2nd Resistance Point 89.48
1st Resistance Point 89.23
Last Price 88.99
1st Support Level 88.72
2nd Support Level 88.46

See More

52-Week High 94.19
Last Price 88.99
Fibonacci 61.8% 85.83
Fibonacci 50% 83.25
Fibonacci 38.2% 80.66
52-Week Low 72.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar